tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NKTR Stock Latest News

Nektar enters research collaboration for NKTR-0165 in multiple sclerosis
The FlyNektar enters research collaboration for NKTR-0165 in multiple sclerosis
4d ago
NKTR
Nektar Therapeutics Prices Upsized Public Equity Offering
PremiumCompany Announcements
Nektar Therapeutics Prices Upsized Public Equity Offering
8d ago
8K
NKTR
Nektar 6.6M share Secondary priced at $58.00
PremiumThe Fly
Nektar 6.6M share Secondary priced at $58.00
9d ago
NKTR
2 Strong Buy Stocks with 90%+ Upside to Buy Now, According to Top Analysts, 2/11/2026
PremiumMarket News
2 Strong Buy Stocks with 90%+ Upside to Buy Now, According to Top Analysts, 2/11/2026
10d ago
AMZN
BETA
Buy Rating on NKTR Driven by Rezpeg’s Strong Phase 2 Maintenance Data and Favorable Risk‑Reward in Atopic Dermatitis
PremiumRatings
Buy Rating on NKTR Driven by Rezpeg’s Strong Phase 2 Maintenance Data and Favorable Risk‑Reward in Atopic Dermatitis
10d ago
NKTR
Nektar announces $300M common stock offering
PremiumThe FlyNektar announces $300M common stock offering
11d ago
NKTR
Nektar price target raised to $151 from $118 at BTIG
Premium
The Fly
Nektar price target raised to $151 from $118 at BTIG
11d ago
NKTR
Nektar upgraded to Outperform from Market Perform at William Blair
Premium
The Fly
Nektar upgraded to Outperform from Market Perform at William Blair
11d ago
NKTR
William Blair upgrades Nektar on durability and deepening of rezpeg response
PremiumThe Fly
William Blair upgrades Nektar on durability and deepening of rezpeg response
11d ago
NKTR
Nektar price target raised to $165 from $135 at H.C. Wainwright
PremiumThe Fly
Nektar price target raised to $165 from $135 at H.C. Wainwright
11d ago
NKTR
Nektar Advances Rezpegaldesleukin After Positive Phase 2b Data
PremiumCompany Announcements
Nektar Advances Rezpegaldesleukin After Positive Phase 2b Data
11d ago
8K
NKTR
Nektar management to meet virtually with Piper Sandler
PremiumThe Fly
Nektar management to meet virtually with Piper Sandler
26d ago
NKTR
Nektar Therapeutics: Share Price Dislocation Masks Rezpeg’s Underappreciated Atopic Dermatitis and Alopecia Areata Upside
PremiumRatingsNektar Therapeutics: Share Price Dislocation Masks Rezpeg’s Underappreciated Atopic Dermatitis and Alopecia Areata Upside
1M ago
NKTR
Nektar management to meet with H. C. Wainwright
Premium
The Fly
Nektar management to meet with H. C. Wainwright
1M ago
NKTR
Septerna appoints Mark Wilson as chief legal officer
Premium
The Fly
Septerna appoints Mark Wilson as chief legal officer
1M ago
NKTR
SEPN
Promising Data from REZOLVE-AA Trial Positions REZPEG as a Safer, Effective Treatment for Alopecia Areata with Undervalued Stock
PremiumRatings
Promising Data from REZOLVE-AA Trial Positions REZPEG as a Safer, Effective Treatment for Alopecia Areata with Undervalued Stock
2M ago
NKTR
Promising Efficacy and Safety of Rezpegaldesleukin Positions Nektar Therapeutics as a Leader in Alopecia Areata Treatment
PremiumRatings
Promising Efficacy and Safety of Rezpegaldesleukin Positions Nektar Therapeutics as a Leader in Alopecia Areata Treatment
2M ago
NKTR
Cautious Hold Rating for Nektar Therapeutics Amid Mixed Rezpeg Trial Results
PremiumRatings
Cautious Hold Rating for Nektar Therapeutics Amid Mixed Rezpeg Trial Results
2M ago
NKTR
Positive Outlook for Nektar Therapeutics Amid Promising Rezpeg Trial Results and Increased Price Target
PremiumRatings
Positive Outlook for Nektar Therapeutics Amid Promising Rezpeg Trial Results and Increased Price Target
2M ago
NKTR
Nektar price target raised to $135 from $120 at H.C. Wainwright
PremiumThe FlyNektar price target raised to $135 from $120 at H.C. Wainwright
2M ago
NKTR
Nektar price target raised to $115 from $98 at Oppenheimer
Premium
The Fly
Nektar price target raised to $115 from $98 at Oppenheimer
2M ago
NKTR
Nektar Therapeutics Announces Phase 2b Trial Results
Premium
Company Announcements
Nektar Therapeutics Announces Phase 2b Trial Results
2M ago
8K
NKTR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >